Study tests immunotherapy plus electroporation for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have stage III pancreatic cancer
- Have a tumor doctors can measure on scans (measurable tumor)
- Have kidney function test showing eGFR above 60 (a blood test measure of kidney filtering)
- Be willing and able to follow the study plan and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This early study tests a combination of chemotherapy and a procedure called irreversible electroporation (IRE) for people with stage III pancreatic cancer. It may help shrink or control tumors, and also studies safety in this group.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This study looks back at people with advanced pancreatic cancer who received a treatment called IRE (a special type of ablation) along with immunotherapy. The goal is to see how well this combination works and how safe it is for patients whose cancer cannot be removed with surgery.
This trial tests a drug combination (AG and nimotuzumab) followed by a procedure called irreversible electroporation (IRE) to treat locally advanced pancreatic cancer that hasn't spread. It aims to see if this approach can help patients whose cancer can't be removed by surgery.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.